Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone720-437-6580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.66 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Aytu Bioscience's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) released its quarterly earnings results on Thursday, February, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.37. The business had revenue of $1.80 million for the quarter, compared to analysts' expectations of $1.58 million. Aytu Bioscience had a negative return on equity of 95.53% and a negative net margin of 217.45%. View Aytu Bioscience's Earnings History.
When is Aytu Bioscience's next earnings date?
What price target have analysts set for AYTU?
1 equities research analysts have issued 12 month target prices for Aytu Bioscience's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Aytu Bioscience's share price to reach $10.00 in the next year. This suggests a possible upside of 481.4% from the stock's current price. View Analyst Price Targets for Aytu Bioscience.
What is the consensus analysts' recommendation for Aytu Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aytu Bioscience.
Has Aytu Bioscience been receiving favorable news coverage?
News coverage about AYTU stock has trended somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aytu Bioscience earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Neos Therapeutics (NEOS), Dyadic International (DYAI), Tissue Regenix Group (TRX), Shield Therapeutics (STX), ANGLE (AGL), Elite Pharmaceuticals (ELTP), Orgenesis (ORGS), Ergomed (ERGO), Cyclopharm (CYC), Invion (IVX), Aptose Biosciences (APTO), Theralase Technologies (TLT), Processa Pharmaceuticals (PCSA), Iterum Therapeutics (ITRM) and Tetraphase Pharmaceuticals (TTPH).
What other stocks do shareholders of Aytu Bioscience own?
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
- Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
- Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)
Who are Aytu Bioscience's major shareholders?
Aytu Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wexford Capital LP (1.04%), Geode Capital Management LLC (0.44%) and Geode Capital Management LLC (0.63%). Company insiders that own Aytu Bioscience stock include David A Green and Jarrett Disbrow. View Institutional Ownership Trends for Aytu Bioscience.
Which major investors are buying Aytu Bioscience stock?
AYTU stock was bought by a variety of institutional investors in the last quarter, including Wexford Capital LP, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Aytu Bioscience stock in the last two years include David A Green and Jarrett Disbrow. View Insider Buying and Selling for Aytu Bioscience.
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $1.72.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $21.42 million and generates $3.66 million in revenue each year. The company earns $-10,180,000.00 in net income (profit) each year or ($27.94) on an earnings per share basis.
What is Aytu Bioscience's official website?
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (NASDAQ AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
